Speaker(s): 

Daniel Kratovil, MD, Resident Physician, Geisinger - has nothing to disclose.

Moderator:

Dana Vanino, MD, Attending Physician, Geisinger - disclosures with Biogen, TG Therapeutics, Novartis, and Alexion

Learning Objectives:

• describe recurrence and post-discharge mortality after an initial SE event
• identify factors associated with SE recurrence and post-discharge mortality

At the conclusion of this session, the participant should be able to answer the following questions:

• Determine how might the findings of this study translate to clinical practice
• Discuss as neurologists, what is the role in addressing patients' non-neurological co-morbidities associated with higher risk of SE recurrence and post-discharge mortality
• Identify any additional information not addressed in this study that should be explored

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Dana Vanino, DO, Cortney Houtz, LPN, Joy Hill, RN, and Sarah Ruhl have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None